Date: 2016-04-27
Type of information: Nomination
Compound:
Company: Medday (France)
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases - Neurological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 27, 2016, MedDay announced the appointment of Catherine Moukheibir as Chairman of its Board of Directors. Catherine will succeed MedDay’s previous Chairman, Jean Jacques Garaud, who contributed to the rapid development of the Company since 2013. The change is effective immediately.
Catherine started her career in strategy consulting and investment banking in Boston and London. She held C-Suite level roles in some of Europe’s leading biotechnology companies. She is currently a member of the management board of Innate Pharma, Chairman of Creabilis and Non-Executive Director at Ablynx, Zealand Pharma and Cerenis.
MedDay’s most advanced pipeline candidate is MD1003 for the treatment of primary and secondary progressive multiple sclerosis.
Financial terms:
Latest news:
